Search Results

You are looking at 31 - 40 of 1,139 items for :

Clear All
Full access

Christopher M. McPherson and Raymond Sawaya

. Neurosurgery 1993 ; 33 : 674 – 678 . 3 Kelly PJ . Stereotactic surgery: what is past is prologue . Neurosurgery 2000 ; 46 : 16 – 27 . 4 Smith KR Frank KJ Bucholz RD . The NeuroStation: a highly accurate, minimally invasive solution

Full access

Matthew P. Banegas, Linda C. Harlan, Bhupinder Mann and K. Robin Yabroff

treated for localized disease, and nearly 30% will be diagnosed with metastatic disease. 2 While surgery remains the primary treatment for localized RCC, 3 treatment options for metastatic RCC have changed markedly in the past decade. Before 2005

Full access

Robert E. Glasgow, David H. Ilson, James A. Hayman, Hans Gerdes, Mary F. Mulcahy and Jaffer A. Ajani

patients have distant metastatic disease, extraregional nodal disease, or T4b tumors (involvement of the heart, great vessels, trachea), or are unable to tolerate surgery or multimodality therapy because of insufficient functional status. Even with optimal

Full access

Quan P. Ly and Aaron R. Sasson

. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy . Ann Surg 2000 ; 232 : 743 – 752 . 9. Yun M Lim

Full access

Joyce Y. Wong and Vernon K. Sondak

Acceptable Option for Invasive Melanoma? Mohs micrographic surgery, traditionally considered contraindicated for invasive melanomas, has been studied in melanoma in situ, particularly in cosmetically sensitive areas such as the head and neck. Using this

Full access

Leigh Selesner, Gabrielle Gauvin, Dorotea Mutabdzic, Eileen O’Halloran, Maxwell Kilcoyne, Kwan-Keat Ang, Jeffrey Farma, Elin Sigurdson and Sanjay Reddy

Introduction: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CS/HIPEC) has led to improved survival in select patients with peritoneal surface malignancies. Predicting the volume of disease and any unresectable disease is

Full access

Katya Losk, Ines Vaz-Luis, Kristen Camuso, Rafael Batista, Max Lloyd, Mustafa Tukenmez, Mehra Golshan, Nancy U. Lin and Craig A. Bunnell

delays in adjuvant chemotherapy initiation greater than 49 to 90 days after surgery may be associated with inferior outcomes, particularly among patients with triple-negative breast cancer (TNBC), HER2-positive subtypes, and higher-stage tumors. 7 – 12 A

Full access

Carlotta Palumbo, Francesco A. Mistretta, Sophie Knipper, Angela Pecoraro, Zhe Tian, Shahrokh F. Shariat, Fred Saad, Claudio Simeone, Alberto Briganti, Alessandro Antonelli and Pierre I. Karakiewicz

probability of survival for x additional years, given y years of accumulated survival. EFS time points used in the CS models consisted of from 1 year up to 10 years after surgery. Second, separate multivariable Cox regression (MCR) models predicting CSM

Full access

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Jordan D. Berlin, J. Michael Berry, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Eric Rohren, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, William Small Jr., Constantinos Sofocleous, James Thomas, Alan P. Venook and Christopher Willett

or presence of regional nodal metastasis. However, because initial therapy of anal cancer does not typically involve surgery, true lymph node status may not be determined accurately. Biopsy of inguinal nodes is recommended if tumor metastasis to these

Full access

Siyana Kurteva, Robyn Tamblyn and Ari Meguerditchian

of cancer patients having undergone surgery in Montreal (Quebec) to describe their post-discharge opioid use and identify potential patterns of unplanned health service use (ED visits, hospitalizations). Provincial health administrative claims were